Milan, Italy

Filippo Canducci

This inventor holds 1 USPTO granted patent and 2 published patent applications and 2 EPO patents. Top assignee: Universitá Degli Studi Di Siena. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Filippo Canducci: Innovator in Antiviral Compounds

Introduction

Filippo Canducci is a notable inventor based in Milan, Italy. He has made significant contributions to the field of medicine, particularly in the development of antiviral compounds. His work focuses on creating effective treatments for diseases caused by enveloped viruses.

Latest Patents

Canducci holds a patent for "Antiviral compounds and use thereof." This invention relates to compounds of formula (I) and their use as medicaments, specifically as broad-spectrum antiviral agents. The compounds are particularly useful in treating diseases caused by enveloped viruses, and they can be combined with other antiviral agents to enhance their effectiveness.

Career Highlights

Throughout his career, Canducci has worked with esteemed institutions such as Università Degli Studi Di Siena and Ospedale San Raffaele S.r.l. His experience in these organizations has allowed him to advance his research and contribute to the medical field significantly.

Collaborations

Canducci has collaborated with notable colleagues, including Valeria Cagno and Annalaura Brai. These partnerships have fostered innovation and have been instrumental in the development of his research.

Conclusion

Filippo Canducci's work in antiviral compounds showcases his dedication to improving healthcare through innovation. His contributions are vital in the ongoing fight against viral diseases, and his patent reflects his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…